Black Diamond Therapeutics Inc at Stifel Targeted Oncology Days (Virtual) Transcript
Good morning, everyone. I'm Bijan Mekoba, senior research associate with Black [Diamond] here at Stifel. Welcome to our Target Oncology Days. We're excited to have the CEO of Black Diamond Therapeutics with us. David Epstein. Thank you for joining us. He'll be discussing the company's lead asset BDTX-1535 and their earlier stage pipeline.
So I'll pass it to you, David.
Well, thank you, Bijan, and good morning, everyone, and thank you for joining. Really delighted to be here. I'll introduce the company. I just want to highlight that this company and the team has had a tremendous amount of experience, both advisers and the people actually carrying out the work in the company in the targeted therapy area. Having all collaborated on the development of Tarceva, one of the first generation EGFR inhibitors approved for the treatment of lung cancer.
I want to remind everybody that this presentation contains forward looking
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |